Thanks for pointing out that post .... very interesting.
I’ll be very curious to see how this all works out - if they’ll provide it to Africa without FDA approval, if FDA will fast-track, etc. It sounds like they might have some ‘supply’ which is usually not the case for the drugs specifically targeted at Ebola.
I saw an interesting comment about the serum given the two at Emory. One medical professional said it worked on Brantly almost like an anti-venom .... rapid response & turnaround in condition. It did not work that fast on Writebol & she needed a second dose. There is a ‘complicating’ factor with looking at the Brantly result - he got a unit of blood from an Ebola survivor before the serum and that should have had antibodies .... was his rapid improvement the result of the two combined?
Ebola is so horrifically deadly - I read the “Hot Zone” years ago and was totally fascinated by it - still have that fascination today, although my heart aches for the victims and their families.
It’s a Japanese drug. Already for sale in Japan. Approved by their own version of the FDA.
Theoretically the FDA would only get involved in its sale in this country.
Why it hasn’t been offered in Africa, from Japan, is a question I’d like to know the answer to.
And another question I’ve got. When our MSM have been discussing possible treatments for ebola, this particular compound is conspicuously absent from their discussions...why?